Not FDA-approved
Brain & sleep
Dihexa
Evidence
Limited human data
Class
Angiotensin IV-derived peptide analog
KEY TAKEAWAY
Dihexa is a synthetic peptide derived from angiotensin IV. It was developed in university research as an experimental memory-enhancing compound. Dihexa is not FDA-approved and has not been tested in controlled human trials.
Written by the Veylo editorial team · Updated
November 2026
What it is
Angiotensin IV-derived peptide analog
Main uses
Studied in animal models of memory loss
Key fact
Dihexa is not FDA-approved and has not been tested in controlled human trials.
Route
Oral and injected forms in animal studies
Evidence strength
Limited human data
Dihexa is a synthetic peptide derived from angiotensin IV. It was developed in university research as an experimental memory-enhancing compound.
In laboratory studies it appears to boost signaling through the hepatocyte growth factor system, which supports new connections between nerve cells.
Dihexa is not FDA-approved and has not been tested in controlled human trials.
Studied in animal models of memory loss.
Because it may promote growth signaling, researchers have raised concerns about cancer risk. No human safety data exist.
Dihexa: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.